FDA Grants Accelerated Approval for Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia
RegulatoryapprovedGenglycosPositive
AI Analysis
Summary
Ultragenyx Pharmaceutical announced FDA accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for Glycogen Storage Disease Type Ia. This regulatory approval represents a significant milestone for the company's rare disease pipeline.
Outcome Details
FDA granted accelerated approval
Importance:9/10
Sentiment:
0.95
FDA approvalaccelerated approvalgene therapyrare diseaseglycogen storage disease
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 19, 2026 10:08 PM